Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Daniel Lundell

Charles A Lunn

Paul J Zavodny

Jimmy C Tan

Barbara Dalie

Xuedong Fan

Arthur G Taveras

Younong Yu

Purakkattle J Biju

Jianhua Chao

Jay S Fine

James P Jakway

John J Baldwin

Ge Li

Michael P Dwyer

Jianping Chao

William Kreutner

Cynthia J Aki

J Robert Merritt

Gaifa Lai

Johan A Ferreira

Loretta A Bober

Bernd Kaiser

Richard W Bond

Minglang Wu

Laura L Rokosz

Kingsley H Nelson, Jr

Evan A Hecker

Motasim Billah

James D Fossetta

Angelo Reggiani

James Jakway

Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).

Treatment of chemokine mediated diseases

The present invention provides isolated human and bovine TNF-&#x3b1; convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&#x3b1;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&#x3b1; convertases, and for identifying nucleic acids encoding such convertases.

Nucleic acids encoding human TNF-&#x3b1; convertase

The present invention provides isolated human and bovine TNF-&#x3b1; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&#x3b1;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&#x3b1; convertases, and for identifying nucleic acids encoding such convertases.

Mammalian TNF-&#x3b1; convertases

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

The present invention provides isolated human and bovine TNF-&agr; convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-&agr;. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-&agr; convertases, and for identifying nucleic acids encoding such convertases.

Mammalian TNF- &agr; convertase

Mammalian TNF-&agr; convertases

The present invention provides isolated human and bovine TNF-.alpha. convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-.alpha.. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-.alpha. convertases, and for identifying nucleic acids encoding such convertases.

Mammalian TNF-.alpha. convertases

Biologically active human inducible nitric oxide synthase (iNOS) is expressed in E. coli. The expression of soluble, active iNOS is dependent on its coexpression with calmodulin.

Expression of human inducible nitric oxide synthase

Growing community of inventors

Flemington, NJ, United States of America

Daniel Lundell